While TGF-β inhibition in combination with anti-PD-1 therapy was found to increase CD8+ infiltration into tumors (Mariathasan et al., 2018), no decrease in CAF levels within the TME or CD8+ levels at the tumor margin was observed in CAF-rich models. The gene discussed is TGFB1; the disease is neoplasm.